{"log_id": 345612749010481047, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.000152, "average": 0.995056, "min": 0.954446}, "location": {"width": 222, "top": 182, "height": 27, "left": 159}, "words": "性增加(见“注意事项”)"}, {"probability": {"variance": 5.2e-05, "average": 0.99463, "min": 0.98237}, "location": {"width": 87, "top": 263, "height": 32, "left": 161}, "words": "[禁忌]"}, {"probability": {"variance": 1.1e-05, "average": 0.997322, "min": 0.984333}, "location": {"width": 468, "top": 306, "height": 36, "left": 191}, "words": "已知对贝那普利、相关化合物或本品的任何辅料过敏者"}, {"probability": {"variance": 0, "average": 0.999567, "min": 0.997664}, "location": {"width": 432, "top": 346, "height": 35, "left": 189}, "words": "有血管紧张素转换酶抑制剂引起血管性水肿病史者"}, {"probability": {"variance": 2e-06, "average": 0.998734, "min": 0.994642}, "location": {"width": 345, "top": 387, "height": 34, "left": 190}, "words": "孕妇(参见“孕妇与哺乳期妇女用药”)"}, {"probability": {"variance": 1.9e-05, "average": 0.996907, "min": 0.988268}, "location": {"width": 138, "top": 469, "height": 37, "left": 161}, "words": "[注意事项]"}, {"probability": {"variance": 1e-06, "average": 0.99877, "min": 0.996253}, "location": {"width": 200, "top": 519, "height": 29, "left": 189}, "words": "过敏样反应和相关反应"}, {"probability": {"variance": 3.7e-05, "average": 0.997824, "min": 0.95987}, "location": {"width": 805, "top": 545, "height": 42, "left": 188}, "words": "因为ACE抑制剂可以影响到类二十烷酸和多肽(包括了内生的缓激肽)的代谢反应,所以服用"}, {"probability": {"variance": 0.000585, "average": 0.994284, "min": 0.837824}, "location": {"width": 835, "top": 581, "height": 45, "left": 159}, "words": "了ACE抑制剂(其中包括了洛汀新°)的病人可能会感到一些不良的反应,其中的部分可能相当严"}, {"probability": {"variance": 0, "average": 0.999612, "min": 0.999612}, "location": {"width": 22, "top": 641, "height": 21, "left": 161}, "words": "重"}, {"probability": {"variance": 1e-06, "average": 0.998784, "min": 0.997679}, "location": {"width": 102, "top": 674, "height": 24, "left": 188}, "words": "血管性水肿"}, {"probability": {"variance": 0.00021, "average": 0.994665, "min": 0.909597}, "location": {"width": 803, "top": 697, "height": 41, "left": 189}, "words": "使用ACE抑制剂(包括洛汀新)已经报告发现过面部、唇部、舌头、声门和喉头的水肿。如出"}, {"probability": {"variance": 2.4e-05, "average": 0.9965, "min": 0.983016}, "location": {"width": 835, "top": 735, "height": 41, "left": 159}, "words": "现该症状,要立即停服本品,并谨慎地监护病人,直到肿胀消失。如果只是发生了面部和唇部的水"}, {"probability": {"variance": 4.7e-05, "average": 0.997011, "min": 0.965067}, "location": {"width": 824, "top": 772, "height": 42, "left": 158}, "words": "肿,这种症状不经过抗组胺或不治疗均可消失。伴喉部水肿和休克的血管水肿可能致命。发生舌"}, {"probability": {"variance": 0.005633, "average": 0.974022, "min": 0.540908}, "location": {"width": 836, "top": 809, "height": 43, "left": 160}, "words": "声门或喉部水肿需要立刻给予适当的治疗,例如皮下注射1:1000.3-0.5mL)肾上腺素溶液或其"}, {"probability": {"variance": 0.000101, "average": 0.995627, "min": 0.961112}, "location": {"width": 256, "top": 857, "height": 31, "left": 161}, "words": "它方法以确保病人呼吸道畅通"}, {"probability": {"variance": 4.4e-05, "average": 0.997815, "min": 0.957421}, "location": {"width": 808, "top": 884, "height": 41, "left": 188}, "words": "在使用ACE抑制剂治疗过程中,源自非洲的黑色人种相比其他人种的病人更加容易发生水肿的"}, {"probability": {"variance": 0, "average": 0.999913, "min": 0.999863}, "location": {"width": 80, "top": 936, "height": 24, "left": 163}, "words": "不良反应"}, {"probability": {"variance": 2e-06, "average": 0.998622, "min": 0.995378}, "location": {"width": 221, "top": 970, "height": 31, "left": 189}, "words": "脱敏治疗中的过敏样反应"}, {"probability": {"variance": 8e-06, "average": 0.998484, "min": 0.983655}, "location": {"width": 810, "top": 998, "height": 41, "left": 189}, "words": "两名服用ACE抑制剂同时接受针对膜翅目昆虫毒素的脱敏治疗的病人发生了致命的过敏样反"}, {"probability": {"variance": 6e-06, "average": 0.998226, "min": 0.990278}, "location": {"width": 838, "top": 1037, "height": 39, "left": 160}, "words": "应。在同样情况的另外一些病人中,及时中断ACE抑制剂的使用可以避免发生上述的反应,但是继"}, {"probability": {"variance": 2.9e-05, "average": 0.996874, "min": 0.982973}, "location": {"width": 160, "top": 1085, "height": 30, "left": 161}, "words": "续用药后反应重现"}, {"probability": {"variance": 0, "average": 0.999482, "min": 0.99772}, "location": {"width": 181, "top": 1124, "height": 25, "left": 190}, "words": "透析中的过敏样反应"}, {"probability": {"variance": 0.004281, "average": 0.987782, "min": 0.569758}, "location": {"width": 809, "top": 1150, "height": 40, "left": 190}, "words": "使用高通透性膜透析的患者,在服用ACE抑制剂时有过敏样反应的报道。此外,对于通过葡聚"}, {"probability": {"variance": 7.3e-05, "average": 0.996874, "min": 0.95944}, "location": {"width": 687, "top": 1190, "height": 38, "left": 162}, "words": "糖硫酸酯吸附进行低密度脂蛋白分离术治疗的病人,同样也有过敏样反应的报告"}, {"probability": {"variance": 0.000167, "average": 0.993456, "min": 0.964679}, "location": {"width": 120, "top": 1239, "height": 25, "left": 192}, "words": "症状性低血压"}, {"probability": {"variance": 7e-06, "average": 0.998467, "min": 0.988314}, "location": {"width": 810, "top": 1264, "height": 40, "left": 191}, "words": "和其它ACE抑制剂一样,罕见发生症状性的低血压。但是因为接受大量利尿剂、对饮食中钠摄"}, {"probability": {"variance": 0.04553, "average": 0.851128, "min": 0.485149}, "location": {"width": 150, "top": 1239, "height": 88, "left": 983}, "words": "量管理部"}, {"probability": {"variance": 4.9e-05, "average": 0.9968, "min": 0.962647}, "location": {"width": 841, "top": 1303, "height": 39, "left": 161}, "words": "入进行控制、接受透析治疗、发生腹泻或者呕吐而导致严重缺钠的或血容量不足时,接受ACE抑制"}, {"probability": {"variance": 7.3e-05, "average": 0.996171, "min": 0.958157}, "location": {"width": 842, "top": 1340, "height": 43, "left": 159}, "words": "剂治疗可能产生低血压。开始用本品治疗前数天停用利尿剂或采取其它措施补充体液,可减少低血"}, {"probability": {"variance": 4.2e-05, "average": 0.996655, "min": 0.969345}, "location": {"width": 840, "top": 1379, "height": 39, "left": 161}, "words": "压的危险。如果确实发生低血压,病人应采取卧位,必要时静注生理盐水。一过性低血压反应不是"}], "language": 3}